Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.

Summary

To evaluate the antiretroviral activity and safety of 200 mg BID and 300 mg BID doses of MPC-4326 administered as monotherapy for 14 days to HIV-1 positive patients. Patients with an initial treatment response will have the option to continue MPC-4326 in combination with an Optimized Backround Regimen for a maximum of 72 weeks.

Timeline

Start

2008-05

Primary completion

2009-11

Completion

2009-12

Drugs

Indications